Purple Biotech (NASDAQ: PPBT) launches new $2.3M ATM ADS sale

Rhea-AI Filing Summary

Purple Biotech Ltd. entered into a new at-the-market equity offering agreement with H.C. Wainwright & Co., LLC, allowing it to sell American Depositary Shares (ADSs), each representing 200 ordinary shares, from time to time through Wainwright as agent. These sales will be made under an existing Form F-3 shelf registration statement, with a prospectus supplement that permits ADS sales of up to an aggregate offering price of $2,300,000.

The company also terminated its prior at-the-market program with Jefferies LLC, which had been in place since 2021. Under the Jefferies program, Purple Biotech sold 983,317 ADSs for aggregate gross proceeds of $7,729,691, at an average price of $7.86 per ADS. The 6-K and its exhibits are incorporated by reference into multiple existing registration statements.

FAQ

What did Purple Biotech (PPBT) disclose in its September 2025 Form 6-K?

Purple Biotech disclosed that it entered into a new at-the-market equity offering agreement with H.C. Wainwright & Co., LLC to sell ADSs from time to time, and that it terminated its previous at-the-market program with Jefferies LLC.

What is the size of Purple Biotech's new ATM program with H.C. Wainwright?

Under the new agreement and related prospectus supplement, Purple Biotech may offer and sell ADSs having an aggregate offering price of up to $2,300,000.

What securities can Purple Biotech sell under the new ATM agreement?

The company may sell American Depositary Shares (ADSs), with each ADS representing 200 ordinary shares of Purple Biotech, no par value.

Which prior ATM program did Purple Biotech terminate and when was it effective?

Purple Biotech terminated its Open Market Sale Agreement with Jefferies LLC, effective as of September 18, 2025, ending its previous at-the-market equity offering program.

How much did Purple Biotech raise under the Jefferies ATM program?

Under the Jefferies at-the-market program, Purple Biotech sold 983,317 ADSs for aggregate gross proceeds of $7,729,691, at an average price of $7.86 per ADS.

Which registration statements does this Form 6-K for Purple Biotech support?

This Form 6-K, including its exhibits, is incorporated by reference into multiple existing Purple Biotech registration statements on Forms S-8 and F-3, including those originally filed in 2016, 2017, 2018, 2019, 2020, 2022, and 2023.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 6-K: How Foreign Companies Report to the SEC →

Accepted by SEC EDGAR 09/19/2025 - 05:28 PM Learn about SEC filing dates

UNITED STATES  

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

of the Securities Exchange Act of 1934

For the month of September 2025

Commission File No.: 001-37643

PURPLE BIOTECH LTD.

(Translation of registrant’s name into English)

4 Oppenheimer Street, Science Park, Rehovot 7670104, Israel

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F ☒      Form 40-F ☐

INFORMATION CONTAINED IN THIS REPORT ON FORM 6-K

Entry into an ATM Agreement

On September 19, 2025, Purple Biotech Ltd. (the “Company”) entered into an “At The Market Offering Agreement (the “ATM Agreement”) with H.C. Wainwright & Co., LLC (“Wainwright”), pursuant to which the Company may offer and sell American Depositary Shares (“ADSs”), each representing two hundred (200) of its ordinary shares, no par value (the “Shares”), from time to time, through Wainwright acting as agent. The offer and sale of the ADSs that may be sold pursuant to the ATM Agreement will be made pursuant to the Company’s shelf registration statement on Form F-3 (File No. 333- 268710), as supplemented by the prospectus supplement dated September 19, 2025, relating to the sale of the ADSs. Pursuant to the prospectus supplement, the Company may offer and sell ADSs having an aggregate offering price of up to $2,300,000.

Termination of the Jefferies ATM Agreement

Effective as of September 18, 2025, the Company terminated the Open Market Sale Agreement entered into with Jefferies LLC in June 2021, for the offer and sale, from time to time, of ADSs through an “at-the-market” equity offering program (the “Jefferies ATM Program”) and pursuant to a prospectus dated May 22, 2023, as supplemented by prospectus supplements, dated October 17, 2023, and January 6, 2025. We sold an aggregate of 983,317 ADSs for aggregate gross proceeds of $7,729,691, at an average price of $7.86 per ADS pursuant to the Jefferies ATM Program.

Attached hereto and incorporated by reference in this Report on Form 6-K are the following exhibits:

Exhibit 1.1:		At The Market Offering Agreement, dated September 19, 2025, between the Company and Wainwright.
Exhibit 5.1:		Opinion of FISCHER (FBC & Co.).
Exhibit 5.2:		Opinion of Haynes and Boone, LLP.
Exhibit 23.1:		Consent of Opinion of FISCHER (FBC & Co.) (included in Exhibit 5.1).
Exhibit 23.2:		Consent of Haynes and Boone, LLP (included in Exhibit 5.2).

This Report on Form 6-K, including all exhibits attached hereto, is hereby incorporated by reference into each of the Registrant’s Registration Statement on Form S-8 filed with the Securities and Exchange Commission on May 20, 2016 (Registration file number 333-211478), the Registrant’s Registration Statement on Form S-8 filed with the Securities and Exchange Commission on June 6, 2017 (Registration file number 333-218538), the Registrant’s Registration Statement on Form F-3, as amended, originally filed with the Securities and Exchange Commission on July 16, 2018 (Registration file number 333-226195), the Registrant’s Registration Statement on Form S-8 filed with the Securities and Exchange Commission on March 28, 2019 (Registration file number 333-230584), the Registrant’s Registration Statement on Form F-3 filed with the Securities and Exchange Commission on September 16, 2019 (Registration file number 333-233795), the Registrant’s Registration Statement on Form F-3 filed with the Securities and Exchange Commission on May 13, 2020 (Registration file number 333-238229), the Registrant’s Registration Statement on Form S-8 filed with the Securities and Exchange Commission on May 18, 2020 (Registration file number 333-238481), each of the Registrant’s Registration Statements on Form F-3 filed with the Securities and Exchange Commission on July 10, 2020 (Registration file numbers 333-239807 and 333-233793), the Registrant’s Registration Statement on Form S-8 filed with the Securities and Exchange Commission on April 4, 2022 (Registration file number 333-264107), the Registrant’s Registration Statement on Form F-3, originally filed with the Securities and Exchange Commission on December 7, 2022 (Registration file number 333-268710), the Registrant’s Registration Statement on Form F-3 filed with the Securities and Exchange Commission on March 23, 2023 (Registration file number 333-270769), and the Registrant’s Registration Statement on Form F-3, originally filed with the Securities and Exchange Commission on May 17, 2023 (Registration file number 333-268710), to be a part thereof from the date on which this report is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.

1

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	PURPLE BIOTECH LTD.
	(the “Registrant”)
Date: September 19, 2025	By:	/s/ Gil Efron
	Name:	Gil Efron
	Title:	Chief Executive Officer

2